Hong Kong Consumer Finance Stock News

Bloks Group (SEHK:325) has just posted its FY 2025 numbers, with second half revenue of C¥1.6b and basic EPS of C¥1.36. Trailing twelve month revenue sits at C¥2.9b and EPS at C¥2.58, all backed by C¥633.7m of net income excluding extra items. The company has seen revenue move from C¥1.2b and a net loss of C¥143.2m in 2H 2024 to C¥1.6b and net income of C¥337.2m in 2H 2025. This shift puts profitability and earnings quality firmly in focus for investors looking at how margins are shaping...

New Silkroad Culturaltainment (SEHK:472) has released its FY 2025 numbers with first half revenue of HK$213.44 million and a basic EPS loss of HK$0.013008, while trailing 12 month figures show revenue of HK$374.72 million and a basic EPS loss of HK$0.0845. Over recent periods, the company has seen revenue move between HK$232.09 million and HK$149.90 million, with basic EPS ranging from small profits of about HK$0.0003 to HK$0.0007 per share. The latest trailing 12 month view shows a return to...

Zhejiang Leapmotor's recent pre-earnings update, ahead of its 16 March 2026 results, has drawn investor attention to margin trends, electric vehicle deliveries, and free cash flow strength as key indicators of its current operating health. This heightened focus on revenue per unit, gross margin quality, and management guidance on volumes and pricing puts Leapmotor’s underlying unit economics and cash generation firmly in the spotlight. We’ll now examine how this intensified focus on...

Why Lepu Biopharma’s Latest Guidance Matters Lepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for 2025, compared with a RMB 411 million loss in 2024. The company links this projected swing to revenue from PUYOUHENG and newly approved MEIYOUHENG, expanded licensing income, and a one off reclassification gain on an investment, while an upcoming March 25 board meeting will review the full 2025 results and...

On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-based mechanism and extended half-life enabling subcutaneous dosing. This IND approval highlights Kelun-Biotech’s growing capabilities in innovative biologics and positions SKB575/HBM7575 as a potentially differentiated long-interval therapy candidate in atopic dermatitis. We will now examine...

Context for Shanghai Junshi Biosciences after recent share performance Shanghai Junshi Biosciences (SEHK:1877) has seen mixed share performance recently, with a small gain over the past week but declines over the past month and past 3 months, drawing attention to how its fundamentals line up. For investors tracking the stock longer term, the shares show a negative total return over 3 and 5 years, while the 1 year total return is positive. This can make current pricing and expectations...

Oshidori International Holdings (SEHK:622) issued new earnings guidance pointing to a net profit of HK$171.4 million for 2025, compared with a HK$194.7 million loss in 2024. This highlights a sharp swing in reported performance. See our latest analysis for Oshidori International Holdings. The guidance appears to sit against very strong recent momentum, with a 30 day share price return of 45.45% and a 90 day gain of 120%, while the 1 year total shareholder return of 266.67% points to sustained...

What recent performance says about Alphamab Oncology Alphamab Oncology (SEHK:9966) has seen mixed share price performance recently, with a 0.6% move over the past day and around 9.6% over the past week, but negative returns over the month and the past 3 months. See our latest analysis for Alphamab Oncology. With the share price at HK$8.6, Alphamab Oncology’s recent 7 day share price return of 9.6% sits against a 30 day decline of 3.4% and a 90 day decline of 19.8%. The 1 year total...

China Chengtong Development Group (SEHK:217) has just posted its FY 2025 first half results, with revenue of HK$205.4 million, basic EPS of HK$0.001659 and net income of HK$9.9 million setting the tone for this reporting season. The company has seen revenue move from HK$323.5 million in 1H 2024 to HK$229.2 million in 2H 2024 and now HK$205.4 million in 1H 2025, while EPS shifted from HK$0.004484 to HK$0.002005 and then HK$0.001659 over the same periods. This gives investors a clear view of...

Investor focus around China Telecom (SEHK:728) has intensified ahead of the 24 March 2026 board meeting, where directors are set to approve 2025 annual results and review a proposed final dividend. See our latest analysis for China Telecom. At a share price of HK$5.09, China Telecom’s 30 day share price return of 3.88% contrasts with a 90 day share price decline of 9.91%. Its 5 year total shareholder return of 166.19% points to a much stronger long term outcome than its 1 year total...

Recent performance snapshot and business profile Robosense Technology (SEHK:2498) has seen mixed share performance recently, with a 1 day return of about a 3% decline and a past 3 months return near an 8% decline, putting its LiDAR focused business under closer investor review. The company reports HK$1,704.246 in revenue and a net loss of HK$382.504, while annual revenue growth is 27.552% and net income growth is very large, reflecting a shift in its loss profile. See our latest analysis for...

Why China Risun Group is back on traders’ radar China Risun Group (SEHK:1907) drew fresh attention after its share price moved sharply higher on 12 March, with trading volumes picking up ahead of the earnings release scheduled for 20 March 2026. See our latest analysis for China Risun Group. That one day move sits on top of a 40.08% 7 day share price return and a 60.71% 90 day share price return, with the latest HK$3.6 level reflecting building short term momentum, even though the 5 year...

Dividend increase and full year results put income focus on CITIC Telecom CITIC Telecom International Holdings (SEHK:1883) has drawn fresh attention after releasing its 2025 results, pairing steady earnings with a slightly higher dividend that may interest income focused investors. See our latest analysis for CITIC Telecom International Holdings. The latest full year earnings and dividend announcement have come alongside a 1 month share price return of 4.23% and an 8.84% year to date share...

Playmates Holdings (SEHK:635) has kicked off FY 2025 with first half revenue of HK$261.1 million and a loss per share of HK$0.10, keeping the focus firmly on the earnings line. Over the last few reporting halves, the toy maker has seen revenue move from HK$526.7 million in 1H 2024 to HK$565.6 million in 2H 2024 and then to HK$261.1 million in 1H 2025. At the same time, losses excluding extra items shifted from HK$159.9 million to HK$222.4 million and then to HK$205.6 million. Investors are...

TOM Group FY 2025 earnings: losses continue but margin picture is shifting TOM Group (SEHK:2383) has reported its FY 2025 first half results with revenue of HK$338.7 million and a basic EPS loss of HK$0.024, while net income excluding extra items came in at a loss of HK$95.0 million, keeping the group in the red. The company has seen revenue move from HK$334.9 million in 1H 2024 to HK$404.7 million in 2H 2024 and HK$338.7 million in 1H 2025, alongside a series of half year EPS losses from...

CITIC Resources Holdings (SEHK:1205) just posted its FY 2025 first half numbers, with revenue of HK$9.4b and basic EPS of HK$0.019, alongside net income of HK$151.7m, giving investors fresh data on how the business is tracking. The company has seen revenue move from HK$3.9b in 1H 2024 to HK$5.6b in 2H 2024 and now HK$9.4b in 1H 2025, while basic EPS shifted from HK$0.045 to HK$0.028 and then HK$0.019 over the same periods. This pattern puts the spotlight firmly on how sustainably the group...

Latest results set up a mixed picture for Tian An Medicare (SEHK:383) Tian An Medicare (SEHK:383) has released its FY 2025 first half numbers, reporting revenue of HK$783.1 million and net income of HK$12.0 million, which translates to basic EPS of HK$0.011. Over the past three reported half year periods, the company has seen revenue move from HK$821.5 million in 1H 2024 to HK$805.7 million in 2H 2024 and HK$783.1 million in 1H 2025. Basic EPS tracked from HK$0.019943 to HK$0.00655 and then...

South Manganese Investment (SEHK:1091) has turned a corner in FY 2025, with first half revenue of HK$2,912.4 million and basic EPS of HK$0.047, after reporting a net income of HK$172.7 million. The company has seen revenue move from HK$5,733.3 million in the first half of 2024 to HK$7,477.2 million in the second half, alongside losses that widened from HK$162.8 million to HK$562.3 million over that period, before the latest return to profit. With the trailing twelve months now profitable and...

YNBY International (SEHK:30) has reported its FY 2025 first half results with revenue of HK$396.4 million and basic EPS of HK$0.00034, putting fresh numbers on the table for investors weighing its recent margin pressure and shareholder dilution. The company has seen revenue move from HK$362.3 million in 1H 2024 to HK$392.6 million in 2H 2024 and HK$396.4 million in 1H 2025, while basic EPS shifted from HK$0.000207 to HK$0.002457 and then HK$0.00034 over the same periods. This sets up a story...

If you are wondering whether BYD at HK$96.75 is a bargain or a value trap, you are not alone. A closer look at how its price lines up with fundamentals can help you frame that question. The stock has returned 2.2% over the last 7 days, but is sitting on a 2.4% decline over 30 days, a 2.0% decline year to date and a 23.9% decline over 1 year, compared with gains of 46.0% over 3 years and 62.2% over 5 years. Recent headlines around BYD have focused on its position in the electric vehicle and...

Recent share performance and business snapshot China Medical System Holdings (SEHK:867) has drawn investor attention after a recent share price pullback, with the stock posting a 4.1% decline over the past day and a 16.3% decline over the past month. Over the past 3 months, the stock has recorded a 6.3% decline, while the 1 year total return stands at 55.1%. In the longer term, the 3 year total return is 13.4% and the 5 year total return reflects a 12.3% decline. The company reports annual...

WuXi Biologics (Cayman) (SEHK:2269) received six company awards and two individual awards at the 2026 Asia Pacific Biopharma Excellence Awards. The company entered a collaboration with Earendil Labs to co develop multiple novel antibody and antibody drug conjugate therapeutics. For investors tracking contract research, development and manufacturing organizations, WuXi Biologics sits at the center of global demand for outsourced biologics work. The new Asia Pacific awards span development,...

Event context and why Geely Automobile matters now Geely Automobile Holdings (SEHK:175) has been in focus after recent trading showed a 1 day decline alongside gains over the past week and month, prompting investors to reassess its current share pricing. See our latest analysis for Geely Automobile Holdings. The recent 1-day share price decline sits against a mixed backdrop, with a 7-day share price return of 6.36% and a year-to-date share price return of a 4.40% decline, while the 3-year...

Stellantis is reported to be in partnership and potential investment talks with Xiaomi and Xpeng regarding electric vehicle cooperation. The discussions could give Xiaomi access to Stellantis production capacity and a pathway into the European EV market. This development comes as investors reassess Xiaomi's role beyond smartphones and consumer devices. Xiaomi, traded as SEHK:1810, is drawing fresh attention as the market considers what a possible tie up with Stellantis could mean for its...